Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.

Templeton, Arnoud J; Omlin, Aurelius; Berthold, Dominik; Beyer, Jörg; Burger, Irene A; Eberli, Daniel; Engeler, Daniel; Fankhauser, Christian; Fischer, Stefanie; Gillessen, Silke; Nicolas, Guillaume; Kroeze, Stephanie; Lorch, Anja; Müntener, Michael; Papachristofilou, Alexandros; Schaefer, Niklaus; Seiler, Daniel; Stenner, Frank; Tsantoulis, Petros; Vlajnic, Tatjana; ... (2023). Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss medical weekly, 153, p. 40108. EMH Schweizerischer Ärzteverlag 10.57187/smw.2023.40108

[img]
Preview
Text
smw-2023-40108.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

The management of prostate cancer is undergoing rapid changes in all disease settings. Novel imaging tools for diagnosis have been introduced, and the treatment of high-risk localized, locally advanced and metastatic disease has changed considerably in recent years. From clinical and health-economic perspectives, a rational and optimal use of the available options is of the utmost importance. While international guidelines list relevant pivotal trials and give recommendations for a variety of clinical scenarios, there is much room for interpretation, and several important questions remain highly debated. The goal of developing a national consensus on the use of these novel diagnostic and therapeutic strategies in order to improve disease management and eventually patient outcomes has prompted a Swiss consensus meeting. Experts from several specialties, including urology, medical oncology, radiation oncology, pathology and nuclear medicine, discussed and voted on questions of the current most important areas of uncertainty, including the staging and treatment of high-risk localized disease, treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and use of new options to treat metastatic castration-resistant prostate cancer (mCRPC).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Beyer, Jörg

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1424-7860

Publisher:

EMH Schweizerischer Ärzteverlag

Language:

English

Submitter:

Pubmed Import

Date Deposited:

21 Aug 2023 15:51

Last Modified:

22 Aug 2023 03:59

Publisher DOI:

10.57187/smw.2023.40108

PubMed ID:

37598311

BORIS DOI:

10.48350/185590

URI:

https://boris.unibe.ch/id/eprint/185590

Actions (login required)

Edit item Edit item
Provide Feedback